A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

Inclusion Criteria:

• Participants must be ≥18 years of age or the country's legal age of majority if thelegal age is more than 18 years at the time of signing the informed consent.

• Participants with histologically confirmed metastatic solid tumour for whom nosuitable alternative standard therapy exists.

• Participants must bear tumours harbouring selected classes of genetic alterations ofMAPK pathway based on an analytically validated assay performed by an accreditedlaboratory.

• Part A: Participants must consent to the use of archival tumour tissue or, if notavailable, collection of fresh tumour biopsy at screening, for central confirmationof mutation status.

• Part B: Participants must consent to the use of archival tumour tissue or, if notavailable, collection of fresh tumour biopsy at screening, for MAPK genomic testingto confirm eligibility.

• Participants must have measurable disease per Response Evaluation Criteria in SolidTumours (RECIST) version 1.1

• Eastern Cooperative Oncology Group (ECOG)/performance status (PS) of 0 or 1

• Contraceptive use by men or women should be consistent with local regulationsregarding the methods of contraception for those participating in clinical studies.

• Capable of giving signed informed consent which includes compliance with therequirements and restrictions listed in the informed consent form (ICF) and in thisprotocol.

Exclusion Criteria:

• Gastrointestinal conditions that could impair absorption of IPN01195 (specific casese.g. remote history of gastrointestinal surgery, may be enrolled after discussionwith the medical monitor)

• Any evidence of severe active infection or inflammatory condition.

• Non-adequate cardiac function

• Known psychiatric or substance abuse disorder, or any other cognitive disorder perthe opinion of the investigator that would interfere with the participant's abilityto cooperate with the requirements of the study.

• Underlying medical conditions that, in the investigator's or sponsor's opinion, willobscure the interpretation of toxicity determination or AEs.

• Known second malignancy either progressing or requiring active treatment within thelast 2 years prior to first dose of the study intervention.

• Active brain metastases or leptomeningeal

• Current enrolment or past participation in any other clinical studies involving aninvestigational study treatment within the last 28 days

• Live vaccine(s) within 28 days prior to first dose of the study intervention or planto receive such vaccines during the study.

• Concurrent treatment with any other anti-cancer therapy (including radiotherapy orinvestigational agents).

• Washout period of less than 28 days prior anti-cancer therapy (includingchemotherapy, targeted agents, radiotherapy). If the participant was treated with anagent having a short half-life, washout can be <28 days but not shorter than 5 timesthe half-life.

• Condition requiring systemic treatment with either corticosteroids (>10 mg dailyprednisone equivalents) or other immunosuppressive medications within 2 weeks priorto first dose of the study intervention.

• Non-adequate bone marrow function

• Non-adequate renal function

• Non-adequate hepatic function

• Known human immunodeficiency virus (HIV) infection. HIV testing will be performed inany countries where mandatory per local requirements.

• Known uncontrolled or untreated hepatitis infection.

• (a) Known uncontrolled hepatitis B virus (HBV) infection.

• (b) Known untreated current hepatitis C virus (HCV) infection.

• Sensitivity to IPN01195 or any of its components.